1. Home
  2. SLP vs AVDL Comparison

SLP vs AVDL Comparison

Compare SLP & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLP
  • AVDL
  • Stock Information
  • Founded
  • SLP 1996
  • AVDL 2015
  • Country
  • SLP United States
  • AVDL Ireland
  • Employees
  • SLP N/A
  • AVDL N/A
  • Industry
  • SLP EDP Services
  • AVDL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLP Technology
  • AVDL Health Care
  • Exchange
  • SLP Nasdaq
  • AVDL Nasdaq
  • Market Cap
  • SLP 675.9M
  • AVDL 784.6M
  • IPO Year
  • SLP 1997
  • AVDL 1996
  • Fundamental
  • Price
  • SLP $17.16
  • AVDL $9.18
  • Analyst Decision
  • SLP Buy
  • AVDL Strong Buy
  • Analyst Count
  • SLP 7
  • AVDL 6
  • Target Price
  • SLP $40.40
  • AVDL $18.17
  • AVG Volume (30 Days)
  • SLP 468.2K
  • AVDL 1.7M
  • Earning Date
  • SLP 07-02-2025
  • AVDL 08-07-2025
  • Dividend Yield
  • SLP 0.35%
  • AVDL N/A
  • EPS Growth
  • SLP N/A
  • AVDL N/A
  • EPS
  • SLP 0.36
  • AVDL N/A
  • Revenue
  • SLP $78,564,000.00
  • AVDL $194,450,000.00
  • Revenue This Year
  • SLP $27.66
  • AVDL $56.88
  • Revenue Next Year
  • SLP $6.75
  • AVDL $29.81
  • P/E Ratio
  • SLP $48.12
  • AVDL N/A
  • Revenue Growth
  • SLP 21.49
  • AVDL 252.64
  • 52 Week Low
  • SLP $17.04
  • AVDL $6.38
  • 52 Week High
  • SLP $49.72
  • AVDL $17.30
  • Technical
  • Relative Strength Index (RSI)
  • SLP 18.67
  • AVDL 47.63
  • Support Level
  • SLP $18.66
  • AVDL $9.10
  • Resistance Level
  • SLP $28.65
  • AVDL $9.76
  • Average True Range (ATR)
  • SLP 1.74
  • AVDL 0.47
  • MACD
  • SLP -1.05
  • AVDL -0.08
  • Stochastic Oscillator
  • SLP 3.78
  • AVDL 14.29

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: